JETEMA Co.,Ltd. Logo

JETEMA Co.,Ltd.

Develops and manufactures toxins, fillers, and threads for the aesthetic medicine market.

216080 | KO

Overview

Corporate Details

ISIN(s):
KR7216080002
LEI:
Country:
South Korea
Address:
강원도 원주시 지정면 조엄로 321, 원주시

Description

JETEMA Co., Ltd. is a research-driven biopharmaceutical company specializing in the development and manufacturing of innovative medicines and medical devices for the aesthetic medicine market. The company's core product portfolio includes botulinum toxins, hyaluronic acid-based dermal fillers, and lifting threads. With a strong focus on research and development, JETEMA aims to provide advanced solutions for anti-aging and aesthetic enhancement. The company's name is derived from the Latin word 'Zetéma', meaning 'research', reflecting its commitment to scientific innovation in creating products for a healthy and beautiful life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 21.8 KB
2025-12-17 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 21.6 KB
2025-12-17 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 21.8 KB
2025-08-27 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 26.5 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-04 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 11.8 KB
2025-06-27 00:00
증권발행결과(자율공시)
Korean 5.6 KB
2025-06-25 00:00
주요사항보고서(전환사채권발행결정)
Korean 70.8 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-05-09 00:00
금전대여결정
Korean 19.3 KB
2025-04-30 00:00
소속부변경
Korean 3.6 KB
2025-04-28 00:00
기타경영사항(자율공시)
Korean 7.6 KB
2025-04-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-04-24 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 29.1 KB
2025-04-15 00:00
주식등의대량보유상황보고서(일반)
Korean 174.7 KB

Automate Your Workflow. Get a real-time feed of all JETEMA Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JETEMA Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JETEMA Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Astria Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapies for allergic and immunologic diseases.
United States of America
ATXS
ATAI Life Sciences N.V. Logo
Develops psychedelic-inspired therapies for mental health disorders.
United States of America
ATAI
Atea Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing oral antiviral therapies for serious viral diseases.
United States of America
AVIR
Athira Pharma, Inc. Logo
Biopharma firm developing small molecule therapeutics for neurodegenerative diseases.
United States of America
ATHA
ATOSSA THERAPEUTICS, INC. Logo
Clinical-stage biopharmaceutical company developing oncology medicines for breast cancer.
United States of America
ATOS
aTYR PHARMA INC Logo
Develops medicines based on tRNA synthetase biology for fibrosis and inflammation.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Develops Virus-Like Drug Conjugates as targeted therapies for solid tumors.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharmaceutical company developing therapies for severe autoimmune diseases.
United States of America
AUPH
AURORA CANNABIS INC Logo
Global producer and distributor of cannabis for medical and recreational markets.
United States of America
ACB
Autolus Therapeutics plc Logo
Biopharmaceutical company developing programmed T cell therapies for cancer and autoimmune diseases.
United States of America
AUTL

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.